Home / People / Bruno Fonteyn
Portrait ofBruno Fonteyn

Bruno Fonteyn

Senior Associate

CMS DeBacker
Chaussée de La Hulpe 178
1170 Brussels
Languages French, Dutch, English

Before joining CMS De Backer’s Public Law department in October 2008, Bruno worked for five years as legal counsel for the National Council of the Order of Physicians.

He specialises in Health law, including regulatory matters, hospitals, medical equipment, medical experiments, bio banks and other Life Science matters. Furthermore, he acts in the areas of constitutional and administrative law.

Bruno is a member of the Ethical Committee of a University Hospital, where he delivers legal opinions on medical experiments and ethical matters.

more less

"Joint practice heads Bruno Fonteyn and Virginie Dor are noted for their expertise in health sector regulation and EU-wide health and social care procurement mandates, respectively."

Legal 500, 2022

Memberships & Roles

  • Legal adviser to the National Council of the Order of Physicians (2003-2008)
  • Member of the Ethical Committee of Erasme Hospital - ULB since March 2008
more less


  •  B. FONTEYN & P. SLEGERS : "Personalized medicine: a major challenge for social security systems", in SCRIP Regulatory Affairs, CUBITT Consulting, 18/06/2014
  • B. FONTEYN & P. SLEGERS : “Distribution & Marketing of Drugs, Jurisdictional comparisons”, European Lawyer Reference, 2013, p. 29
  • B. FONTEYN & C.DUBOIS : "La plate-forme eHealth – Enjeux de santé publique et de sécurité sociale", Journal des Tribunaux, 24/11/2012, n° 6498,  p. 769 à 776
  • B. FONTEYN & P. SLEGERS : "La directive 2011/24/UE relative à l’application des droits des patients en matière de soins de santé transfrontaliers : bien plus qu’une codification", European Journal of Consumer Law, Larcier, n° 1/2012, p. 61-79
more less


  • 2008 - Bar admission (Brussels, Belgium)
  • 2003 - University of Sherbrooke - Canada
  • 2003 - Université Catholique de Louvain, UCLouvain - Belgium (Law Degree)
more less


Cannabis law and legislation in Belgium
Medical use In principle, the cultivation, import, sale and possession of (medicinal or recreational) cannabis is not allowed under Belgian law. An exception is made for the cultivation of hemp with a...
Adapting to the new EU Data Act: implications for medical devices and other...
In recent years, the European Commission developed a European data strategy, which aims to create a single European market in which data can circulate freely. As the European Commission has emphasized...
Belgian DPA again clarifies the right of access to medical records
In its decision of 6 December 2022, the Belgian Data Protection Authority (“BDPA”) issued a reminder of the limits attached to the right of access to medical records, including personal notes of the...
Belgian DPA clarifies the interaction between Belgian Patient's Rights...
In its decision of 6 July 2022, the Belgian Data Protection Authority (BDPA) has issued a reminder of the limits attached to the right of access and right to rectification of medical records. Available...
CMS Belgium and CMS France advised Gryphon Investors on their acquisition...
CMS Belgium and CMS France successfully advised, alongside Kirkland & Ellis, Gryphon Investors (“Gryphon”), a leading middle-market private equity firm, on the Belgian and French aspects of Gryphon’s...
CMS Belgium and CMS France advised Biogroup in connection with the acquisition...
CMS Belgium and CMS France advised Biogroup in connection with the acquisition of the Belgian clinical lab Group CMA-Medina. With this acquisition, the largest private clinical blood analysis groups in...
The creation of local hospital networks subject to merger control
The Belgian Competition Authority published on 22 July 2020 its position on the application of merger control to local hospital networks. On this occasion, the Authority recalls the obligation for the...
CMS Global Life Sciences & Healthcare Forum 2019
 We have the pleasure to cordially invite you to our    on Thursday, 21 November 2019, at 09:30 CET in Frankfurt. The Forum will provide insights from external experts and CMS specialists on four core...
The Belgian Competition Authority condemns the Order of Pharmacists for...
On 28 May 2019, the Belgian Competition Authority ruled that the Order of Pharmacists had used its influence to hinder the business activities of the innovative pharmacy and parapharmacy chain Medi­Care-Mar­ket...
Consumer Products Newsletter
Below you will find the topics of the news­let­ter:EUROPEAN UNION ARTICLESEU 'New Deal for Consumers' is ComingEuropean Court of Justice – Consumers can Withdraw their Purchases of Online Mattresses even...
Belgium submits draft bill on distributing medicinal cannabis
EU continues fight against falsified medicines
Following the European Falsified Medicines Directive, new safety measures entered into force in the EU on 9 February 2019 that guarantee the identification and authenticity of medicinal products and must...